jump to navigation

David Fazzolare Quoted in FDA Week Biosimilar Article 08/12/2014

Posted by Morse, Barnes-Brown Pendleton in Attorney News, Intellectual Property, Legal Developments, Life Sciences.
Tags: , , , , , ,
add a comment

Patent Attorney David FazzolareOn August 8th InsiderHealthPolicy.com’s FDA Week, an exclusive weekly report on Food and Drug Administration Policy, regulation and enforcement, published an article titledBiosimilar ‘Patent Dance,’ Litigation Could Coincide With Possible Approval. The article discusses the FDA’s recent acceptance of the first biosimilar application from Sandoz for a biosimilar filgrastim, a version of Amgen’s Neupogen. This acceptance of Sandoz’s application has also set off a series of deadlines outlined in statute that will determine which patents the two companies will litigate. MBBP Patent Attorney David Fazzolare was quoted in the article discussing the patent exchange process including several other deadlines before possibly resulting in litigation. David stated:

The earliest that I see anything publicly happening, absent any press releases from Sandoz and Amgen, is March of next year.

The same two companies are currently engaged in litigation over patents related to a different product, Enbrel, which is currently on appeal in the U.S. Court of Appeals for the Federal Circuit and oral arguments are slated for Sept. 10.

For more information on this topic, please contact David Fazzolare.

USPTO Provides Further Guidance on Proposed Three Track Examination Initiative 02/14/2011

Posted by Morse, Barnes-Brown Pendleton in Attorney News, Legal Developments.
Tags: , ,
add a comment

By Daniel McGeeney and Stan Chalvire

In a Press Release issued on February 2, 2011, the U.S. Patent and Trademark Office (USPTO) announced updates to its proposed “Three Track” examination initiative. This initiative was proposed by the USPTO in June 2010 (75 Fed. Reg. 31763) to provide applicants some control over the timing of the examination of their patent applications. The proposed initiative aims to provide applicants with the type of examination they need and to reduce the overall pendency of patent applications, which presently stands at almost three years.

Patent Attorney Stan ChalvireGenerally, the proposed Three Track examination initiative would allow applicants to: (1) request prioritized examination of a non-continuing application within twelve months of their filing date (Track I); (2) request that an application that does not claim the benefit of a prior-filed foreign application or a prior non-provisional application be placed in an applicant-controlled up to 30 month queue prior to docketing for examination (Track III); or (3) make neither of the Track I or Track III requests and proceed in accordance with the current standard procedure (Track II).

For the full article on this subject, please visit our website.

For more information or to discuss the USPTO’s proposed Three Track examination initiative, as well as other strategies for expediting the examination of your patent application, please contact Daniel McGeeney or Stan Chalvire.

Stanley Chalvire to Speak at Pharmaceutical Patent Protection and Enforcement Conference 09/17/2010

Posted by Morse, Barnes-Brown Pendleton in Attorney News, Events.
Tags: ,
add a comment

Patent Attorney Stan ChalvireOn September 27-28, Q1 Productions is hosting the Pharmaceutical Patent Protection and Enforcement Conference in Baltimore, Maryland. The conference will bring together members of the pharmaceutical industry, patent attorneys and high ranking governmental officials to discuss current patent cases, how to protect and prolong patent exclusivity, and debate the industry’s future. MBBP Patent Attorney Stanley Chalvire will be presenting on “US Patent Law: Inequitable Conduct and Duty of Candor”.

To learn more about the event or to register, please contact Paul Hernandez or call 312-602-9683.

For questions on pharmaceutical patents, please contact Stanley Chalvire.

Intellectual Property Today Lists MBBP in Top 100 U.S. Trademark Firms 05/17/2010

Posted by Morse, Barnes-Brown Pendleton in Client News, MBBP news.
Tags: ,
add a comment

Intellectual Property Today recently named Morse, Barnes-Brown & Pendleton, P.C. (MBBP) as one of the Top Trademark Firms in the United States for the year 2010. The firms are ranked “according to the number of trademark registrations issued in 2009 where the firm or individual is listed as the legal representative on the registration.” MBBP came in at #94 with 116, 166 and 145 trademark registrations in 2007, 2008 and 2009 respectively.

Please see the Top Trademark Firms list for more information.

MBBP’s Stan Chalvire to Speak at MDG “The Power of Trade Secrets” 03/24/2010

Posted by Morse, Barnes-Brown Pendleton in Attorney News, Events.
Tags: ,
add a comment

Patent Attorney Stan ChalvireOn April 21, 2010, MBBP attorney Stan Chalvire has been asked to speak at the Medical Development Group networking event, “The Power of Trade Secrets: When Not to Patent Your Invention”. Stan will discuss what you can do when patents are not available for your invention, or just the best way to protect your asset (and why).

To learn more about this event, please visit Medical Development Group.

For more information on patents, please contact Stan Chalvire.

Follow

Get every new post delivered to your Inbox.

Join 48 other followers

%d bloggers like this: